Grow Your Pharma Business Digitally
Weekly News Recap #Phispers
Stock Recap #PipelineProspector
Virtual Booth
Contact Supplier
Check COS databaseCheck USDMF database
Contact UsPharmaScopic.com
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EN-2642
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enosi Therapeutics to Present at the ENA 2022 Symposium on Molecular Targets and Cancer Therapeutics in Barcel...
Details : EN-2642 is an affinity EGFR-Fc: HER3:Fc ligand trap and binds 9 of 11 growth factors which activate HER family.Growth factors participate in progression of many diseases, including solid cancers and rheumatoid arthritis.
Product Name : EN-2642
Product Type : Protein
Upfront Cash : Inapplicable
October 24, 2022
Highest Development Status : Discovery
Stock Recap#PipelineProspector
Data Compilation#PharmaFlow